An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer

Trial Profile

An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2016

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors BIND Therapeutics
  • Most Recent Events

    • 14 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 07 Jan 2016 Results from this trial were presented at the 2016 Genitourinary Cancers Symposium, according to a BIND Therapeutics media release.
    • 07 Jan 2016 Results published in a BIND Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top